The Technical Analyst
Creative Medical [CELZ]
Exchange: PNK Industry: Biotechnology
Creative Medical Price, Forecast, Insider, Ratings, Fundamentals & Signals
-6.29% $4.40
America/New_York / 3 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.96 mill |
| EPS: | -3.76 |
| P/E: | -1.170 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 1.357 mill |
| Avg Daily Volume: | 0.211 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.170 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -1.170 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.44 (-44.43%) $-1.953 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.97 - 4.82 ( +/- 9.68%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-28 | Warbington Timothy | Buy | 200 | Common Stock |
| 2023-06-27 | Warbington Timothy | Buy | 200 | Common Stock |
| 2023-06-27 | Warbington Timothy | Buy | 300 | Common Stock |
| 2023-06-27 | Warbington Timothy | Buy | 300 | Common Stock |
| 2022-11-22 | Warbington Timothy | Buy | 200 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 87 transactions |
| Buy: 1 523 518 267 | Sell: 49 173 266 |
Forecast:
16:00 - $4.40
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.40
Forecast 2: 16:00 - $4.40
Forecast 3: 16:00 - $4.40
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $4.40 (-6.29% ) |
| Volume | 0.0050 mill |
| Avg. Vol. | 0.211 mill |
| % of Avg. Vol | 2.39 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CELZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CELZ
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Latest Press Releases
2024-03-27 09:00:00 - Press Release
Creative Medical Technology Holdings Provides Corporate Update
Phoenix--(business wire)--creative medical technology holdings, inc., (“creative medical technology” or the “company”) (nasdaq: celz), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of its form 10-k on march 22, 2024. “in the past year our achievements have been some of the most consequential in the history of creative medical technology,” said timot.
2024-03-07 09:15:00 - Press Release
Creative Medical Technology Holdings Inc. Announces Fda Authorization For Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
Phoenix--(business wire)--creative medical technology holdings, inc., (nasdaq:celz), a leader in biotech innovation, today announced a major stride in combating type 1 diabetes mellitus (t1d). the company has secured fda authorization for an expanded access therapy using celz-201, a pioneering cell-based program in managing abnormal glucose tolerance and preventing t1d in high-risk individuals. this groundbreaking therapy uses celz-201 to potentially prevent t1d onset and is believed to be a fi.
2024-03-06 07:00:00 - Press Release
Creative Medical Technology Holdings, Inc. Receives Fda Orphan Drug Designation For Celz-101 In Key Transplantation Therapy
Phoenix--(business wire)--creative medical technology holdings, inc. (nasdaq: celz), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of orphan drug designation from the u.s. food and drug administration (fda) for celz-101, immcelztm. this cutting-edge therapy is aimed at preventing allograft rejection in patients undergoing pancreatic isl.
2023-12-21 08:57:48 - Press Release
Creative Medical Technology Granted Fda Clearance For Chronic Back Pain Clinical Trial
New york, december 21, 2023 – creative medical technology holdings, inc. (nasdaq: celz) has received fda clearance to conduct a phase 1/2 clinical trial using the company's innovative stemspine® treatment known as allostem™ (celz-201-ddt).
2023-12-20 09:35:00 - Press Release
Creative Medical Technology Holdings (nasdaq:celz) Granted Fda Clearance To Begin Phase 1/2 Clinical Trial Of Allostem(tm) For Addressing Chronic Lower Back Pain
Phoenix, az / accesswire / december 20, 2023 / creative medical technology holdings, inc. (nasdaq:celz), a biotechnology company has received clearance from the fda to conduct a phase 1/2 clinical trial using their innovative stemspine® treatment known as allostem™. this study aims to determine the safety, efficacy and tolerability of celz-201-ddt, a proprietary, ready-to-use cell line developed by the company.
Latest News
2024-03-07 12:06:03 - Zacks Investment Research
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.
2023-09-22 13:31:19 - Zacks Investment Research
What Makes Creative Medical Technology Holdings, Inc. (CELZ) a New Buy Stock
Creative Medical Technology Holdings, Inc. (CELZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-04-13 13:39:36 - Zacks Investment Research
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data
Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.
2023-04-13 06:00:00 - PennyStocks
3 Methods for Finding Penny Stocks to Buy and Hold
Use these strategies for making money with penny stocks in 2023 The post 3 Methods for Finding Penny Stocks to Buy and Hold appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-02-08 10:40:28 - InvestorPlace
Why Is Creative Medical (CELZ) Stock Up 121% Today?
Creative Medical (NASDAQ: CELZ ) stock is rocketing higher on Wednesday thanks to clearance for a new clinical trial. That clearance comes from the FDA and covers CELZ-201 cell therapy.
2023-02-08 09:38:45 - PennyStocks
Penny Stocks To Buy Now? 5 To Watch After News This Week
Stock Market News Has These Penny Stocks On Traders' Watch Lists This Week. The post Penny Stocks To Buy Now?
2022-06-30 20:00:20 - PennyStocks
Penny Stocks to Watch as June Comes to an End
Are these penny stocks on your watchlist right now? The post Penny Stocks to Watch as June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-21 11:27:15 - PennyStocks
Penny Stocks To Buy? 8 Short Squeeze Stocks To Watch Now
2022-04-20 10:23:35 - PennyStocks
Best Penny Stocks To Buy Now? 5 Short Squeeze Stocks To Watch
2022-03-31 15:17:27 - PennyStocks
Trending Penny Stocks to Buy Now, 3 to Watch During Trading in April
Check these three trending penny stocks out for your watchlist right now The post Trending Penny Stocks to Buy Now, 3 to Watch During Trading in April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.